Strategic Commercial Partnerships Transforming the Global Biobanking Market, 2020–2026

Strategic Commercial Partnerships Transforming the Global Biobanking Market, 2020–2026

Precision Medicine Applications and Value-based Data Pricing with Pharma and Health-tech to Trigger Market Growth

RELEASE DATE
12-Aug-2020
REGION
North America
Research Code: MFA8-01-00-00-00
SKU: HC03323-NA-MT_24623

$4,950.00

Special Price $4,207.50 save 15 %

In stock
SKU
HC03323-NA-MT_24623

$4,950.00

$4,207.50 save 15 %

DownloadLink

Pay by invoice

ENQUIRE NOW

Description

The biobanking ecosystem is witnessing significant transformation. Emergence of one-stop shops and virtual biobanks, rise in services offered to sustain and improve positioning, and precision medicine are characterizing this transformative environment. The biobanking market is expected to reach a size of ~$71.2 billion by 2026, registering a compound annual growth rate (CAGR) of ~5.2% from 2020. While Europe is the highest contributor to the total market, Asia-Pacific (APAC) is expected to witness the highest growth during the forecast period (2020 to 2026) of this research. This market will be driven further by innovation in targeted therapeutic applications, high sample utilization of tissue/stem cells, and the increasing demand for bio-data for enabling patient stratification. Significant growth opportunities for biobanks are in the areas of companion diagnostics (CDx) co-development, large-scale genome sequencing projects, immuno-oncology clinical development, digital pathology services, and real-world evidence (RWE) studies.

The shifting industry paradigm towards commercial partnerships with pharmaceutical and biotech companies, contract research organizations (CROs), and contract development and manufacturing organizations (CDMOs), as well as diagnostics and digital solution providers is expected to further boost market growth. Biobanks are partnering with end-users for customized research-based engagements as niche providers of samples and services and as data owners. However, they need to better understand the changing end-user needs and transition to innovative value-based data pricing and hybrid models for ensuring operational sustainability in the future. Collaborations with commercial partners by fulfilling key selection criteria and engaging with well-defined models are a critical requirement for biobanks to retain market share. A number of leading biobanks in the United States, the United Kingdom, Sweden, and Denmark have taken major strides in adopting and implementing industry best practices in the last few years.

Author: Unmesh Lal

RESEARCH: INFOGRAPHIC

This infographic presents a brief overview of the research, and highlights the key topics discussed in it.
Click image to view it in full size

Table of Contents

Why Is It Increasingly Difficult to Grow?

The Strategic Imperative 8™

The Impact of the Top Five Strategic Imperatives on the Biobanking Industry

The Impact of the Top Five Strategic Imperatives on the Biobanking Industry (continued)

Growth Opportunities Fuel the Growth Pipeline Engine™

Biobanking Market, Scope of Analysis

Biobanking Market, Scope of Analysis (continued)

Biobanking Market, Scope of Analysis—COVID-19 Impact

Biobanking Market, Scope of Analysis—Key Market Themes

Biobanking Market, Scope of Analysis—Value Chain & Key Stakeholders

Biobanking Market, Scope of Analysis—Workflow Optimization

Biobanking Market, Scope of Analysis—Future Role of Biobanks

Biobanking Market, Scope of Analysis—Future Role of Biobanks (continued)

Biobanking Market, Scope of Analysis—Future Role of Biobanks (continued)

Biobanking Market, Segmentation

Key Competitors and End-users in the Biobanking Market

Key Growth Metrics for the Biobanking Market

Growth Drivers for the Biobanking Market

Growth Driver Analysis for the Biobanking Market

Growth Driver Analysis for the Biobanking Market (continued)

Growth Restraints for the Biobanking Market

Growth Restraint Analysis for the Biobanking Market

Market Forecast Assumptions, Methodology—Biobanking Market

Revenue Forecast, Biobanking Market

Revenue Forecast Analysis by Region, Biobanking Market

Revenue Forecast Analysis by Region, Biobanking Market (continued)

Revenue Forecast Analysis by Region, Biobanking Market (continued)

Revenue Forecast Analysis by Region, Biobanking Market (continued)

Revenue Forecast Analysis by Region, Biobanking Market (continued)

Revenue Forecast Analysis by Region, Biobanking Market (continued)

Revenue Forecast by Application

Percent Revenue Share by Application

Revenue Forecast by Biobank Type

Percent Revenue Share by Biobank Type

Revenue Forecast by Sample Type

Percent Revenue Share by Sample Type

Revenue Forecast by Ownership Type

Percent Revenue Share by Ownership Type

Stakeholder Engagement, Biobanking Market

Pricing Analysis, Biobanking Market

Pricing Analysis, Biobanking Market (continued)

End-user Analysis, Biobanking Market

Competitive Environment, Biobanking Market

Competitive Environment, Biobanking Market (continued)

Competitive Environment, Biobanking Market (continued)

Competitive Environment, Biobanking Market (continued)

Competitive Environment, Biobanking Market (continued)

Top 5 Growth Opportunities

Growth Opportunity 1: Companion Diagnostics Co-Development for Biomarker-based Therapeutics, 2020

Growth Opportunity 1: Companion Diagnostics Co-Development Analysis, 2020

Growth Opportunity 2: Bio-data for Large-scale Genome Sequencing Projects, 2020

Growth Opportunity 2: Large-scale Genome Sequencing Analysis, 2020

Growth Opportunity 3: Human Tissue/Tumor Cells for Oncology Clinical Development, 2020

Growth Opportunity 3: Oncology Clinical Development Analysis, 2020

Growth Opportunity 4: Digital Pathology and Imaging Services, 2020

Growth Opportunity 4: Digital Pathology and Imaging Analysis, 2020

Growth Opportunity 5: RWE Studies for Product Commercialization, 2020

Growth Opportunity 5: RWE Analysis, 2020

Your Next Steps

Why Frost, Why Now?

List of Exhibits

Legal Disclaimer

Related Research
The biobanking ecosystem is witnessing significant transformation. Emergence of one-stop shops and virtual biobanks, rise in services offered to sustain and improve positioning, and precision medicine are characterizing this transformative environment. The biobanking market is expected to reach a size of ~$71.2 billion by 2026, registering a compound annual growth rate (CAGR) of ~5.2% from 2020. While Europe is the highest contributor to the total market, Asia-Pacific (APAC) is expected to witness the highest growth during the forecast period (2020 to 2026) of this research. This market will be driven further by innovation in targeted therapeutic applications, high sample utilization of tissue/stem cells, and the increasing demand for bio-data for enabling patient stratification. Significant growth opportunities for biobanks are in the areas of companion diagnostics (CDx) co-development, large-scale genome sequencing projects, immuno-oncology clinical development, digital pathology services, and real-world evidence (RWE) studies. The shifting industry paradigm towards commercial partnerships with pharmaceutical and biotech companies, contract research organizations (CROs), and contract development and manufacturing organizations (CDMOs), as well as diagnostics and digital solution providers is expected to further boost market growth. Biobanks are partnering with end-users for customized research-based engagements as niche providers of samples and services and as data owners. However, they need to better understand the changing end-user needs and transition to innovative value-based data pricing and hybrid models for ensuring operational sustainability in the future. Collaborations with commercial partners by fulfilling key selection criteria and engaging with well-defined models are a critical requirement for biobanks to retain market share. A number of leading biobanks in the United States, the United Kingdom, Sweden, and Denmark have taken major strides in adopting and implementing industry best practices in the last few years. Author: Unmesh Lal
More Information
No Index No
Podcast No
Author Unmesh Lal
Industries Healthcare
WIP Number MFA8-01-00-00-00
Is Prebook No
GPS Codes 9564-B1,9575-B1,9600-B1,9612-B1,9562-B1,9571-B1,9573-B1,99BC-B1,99C1-B1,99C6-B1,9568-B1,9611-B1,9627-B1